•  
  •  
 

Abstract

Hypertension (HTN) is one of the major contributing factors associated with the progression and development of cardiovascular disease (CVD). Moreover, HTN is expected to significantly increase by the year 2050. Nitrate supplements such as beetroot juice (BRJ) have been utilized as a dietary therapeutic to mitigate the progression of HTN and CVD; however, arugula extract, which has a higher nitrate content, has yet to be assessed. PURPOSE: The purpose of this study was to assess the effects of arugula extract on cardiovascular health measures in hypertensive individuals.  METHODS: 12 participants (M = 11; F = 1) with stage 1 HTN in accordance with the AHA participated in this placebo-controlled crossover design study. Participants were randomized to begin the assessment with either 4000mg of arugula extract or placebo supplement. Heart rate, blood pressure, and blood samples were collected at four timepoints (baseline, 1-HR, 2-HR, 3-HR, 24-HR) following ingestion. Flow mediated dilation (FMD) was collected at three timepoints (baseline, 3-HR, 24-HR) or each visit. Following the completion of the condition, a 72-HR washout period was utilized prior to reporting for the second condition. RESULTS: Mean SBP was significantly lower in arugula condition 1-HR, 2-HR, 3-HR, and 24-HR compared to the placebo group (p < .001), with a peak reduction at 3-HR (-12.96mmHg; p < .001; 95% CI: 10.31, 15.62) and a sustained reduction at 24-HR (9.5mmHg; p < .001; 95% CI: 6.85, 12.16). Total NO and concentrations increased from baseline to 3-HR (56.72µM; p < .001; 95% CI: 50.16, 63.27) compared to the placebo. Nitrate concentrations also increased from baseline to 3-HR (55.75µM; p < .001; 95% CI: 49.13, 62.36) compared to the placebo. FMD in the arugula condition improved at 3-HR (1.8%; p < .001; 95% CI: 0.96, 2.62) and 24-HR (1.6%; p < .001; 95% CI: 0.82, 2.49) post ingestion compared to the control.  CONCLUSION: Arugula extract supplementation was able to significantly improve cardiovascular health parameters in individuals with stage 1 HTN. This study demonstrated the AE’s potential as dietary therapeutic to stimulate reductions in SBP, improvement endothelial function, and increase in NO/nitrate concentrations. Future studies should assess the efficacy of prolonged AE supplementation on long-term cardiovascular measures in hypertensive individuals.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.